Physicians are a privileged group entrusted with an unshrouded view ofour patients' minds and bodies and the relatively autonomous capabilityof prescribing various managements, medicines, and procedures. For example, patients often willingly accept our recommendation for choiceof competing treatments based on their confidence in our medical opinion.This profound trust is granted to us by society because of an educationgained in part by their generosity (as tax payers, benefactors, and trainingsubjects during our learning curve) and thus requires a high level of responsibilityto prescribe management choices that are intrinsically best for each individualpatient without regard to our own financial interest.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.